Aura Biosciences completes Phase 3 bel-sar trial enrollment; topline data expected in 2H 2027
Aura Biosciences reported all participants have completed the Phase 3 CoMpass bel-sar trial on track for topline data in late 2027. The strong operational execution and pipeline progress maintains market relevance for the ocular oncology biotech.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed